

United States Department of Agriculture
Center for Veterinary Biologics
Testing Protocol

SAM 109

Supplemental Assay Method for the Titration of Bovine Rhinotracheitis
Neutralizing Antibody (Constant Virus-Varying Serum Method)

Date: October 16, 2014
Number: SAM 109.05
Supersedes: SAM 109.04, September 9, 2011
Standard Requirement: 9 CFR 113.216
Contact: Alethea M. Fry, (515) 337-7200
Peg A. Patterson

Approvals:

/s/Geetha B. Srinivas Date: 01Dec14
Geetha B. Srinivas, Section Leader
Virology

/s/Byron E. Rippke Date: 03Dec14
Byron E. Rippke, Director
Policy, Evaluation, and Licensing
Center for Veterinary Biologics

/s/Rebecca L.W. Hyde Date: 08Dec14
Rebecca L.W. Hyde, Section Leader
Quality Management
Center for Veterinary Biologics

United States Department of Agriculture
Animal and Plant Health Inspection Service
P. O. Box 844
Ames, IA 50010

Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA
and does not imply its approval to the exclusion of other products that may be suitable.

UNCONTROLLED COPY

Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)

Table of Contents

- 1. Introduction**
- 2. Materials**
 - 2.1 Equipment/instrumentation**
 - 2.2 Reagents/supplies**
- 3. Preparation for the Test**
 - 3.1 Personnel qualifications/training**
 - 3.2 Preparation of equipment/instrumentation**
 - 3.3 Preparation of reagents/control procedures**
 - 3.4 Preparation of the Test Serum, PCS, and NCS**
- 4. Performance of the Test**
- 5. Interpretation of the Test Results**
- 6. Report of Test Results**
- 7. References**
- 8. Summary of Revisions**

Appendices

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

1. Introduction

This Supplemental Assay Method (SAM) describes an *in vitro* test of serum for the serum neutralization (SN) antibody titer against bovine rhinotracheitis virus (IBR). The assay uses a constant amount of virus to test varying dilutions of serum in a cell culture system. The assay meets the requirements in title 9, *Code of Federal Regulations* (9 CFR), part 113.216, to test serum samples for potency testing of inactivated IBR vaccines.

Note: For this SAM, the dilution terminology of 1:2, 1:4, etc. specifies 1 part + 1 part (liquid), 1 part + 3 parts, etc.

2. Materials

2.1 Equipment/instrumentation

Equivalent equipment or instrumentation may be substituted for any brand name listed below.

2.1.1 Incubator, $36^{\circ} \pm 2^{\circ}\text{C}$, $5\% \pm 1\% \text{CO}_2$, high humidity (Model 3158, Forma Scientific, Inc.)

2.1.2 Vortex mixer (Vortex-2 Genie, Model G-560, Scientific Industries, Inc.)

2.1.3 Microscope, inverted light (Model CK, Olympus America, Inc.)

2.1.4 Micropipettor, 200- μL , 500- μL , 1000- μL and tips

2.1.5 Water bath

2.2 Reagents/supplies

Equivalent reagents or supplies may be substituted for any brand name listed below. All reagents and supplies must be sterile.

2.2.1 IBR Reference virus, Cooper strain

2.2.2 Madin-Darby bovine kidney (MDBK) cells

2.2.3 Minimum essential medium (MEM)

1. 9.61 g MEM with Earles salts without bicarbonate

2. 2.2 g sodium bicarbonate (NaHCO_3)

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

- 3.** Dissolve **Steps 1 and 2** with 900 mL deionized water (DI).
- 4.** Add 5 g lactalbumin hydrolysate or edamine to 10 mL DI. Heat to $60^{\circ}\pm 2^{\circ}\text{C}$ until dissolved. Add to **Step 3** with constant stirring.
- 5.** Q.S. to 1000 mL with DI; adjust pH to 6.8-6.9 with 2N hydrochloric acid (HCl).
- 6.** Sterilize through a 0.22- μm filter.
- 7.** Aseptically add:
 - a.** 10 mL L-glutamine
 - b.** 50 $\mu\text{g}/\text{mL}$ gentamicin sulfate
- 8.** Store at $4^{\circ}\pm 2^{\circ}\text{C}$.

2.2.4 Growth Medium

- 1.** 900 mL of MEM
- 2.** Aseptically add 100 mL gamma-irradiated fetal bovine serum (FBS)
- 3.** Store at $4^{\circ}\pm 2^{\circ}\text{C}$.

2.2.5 Maintenance Medium

- 1.** 980 mL of MEM
- 2.** Aseptically add 20 mL of gamma-irradiated FBS
- 3.** Store at $4^{\circ}\pm 2^{\circ}\text{C}$.

2.2.6 Positive IBR control serum (PCS)

2.2.7 Negative IBR control serum (NCS)

2.2.8 Cell culture plates, 96-well

2.2.9 Polystyrene tubes, 12 x 75-mm

UNCONTROLLED COPY

Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)

3. Preparation for the Test

3.1 Personnel qualifications/training

Personnel must have training in antibody titration assays, cell culture maintenance, and in the principles of aseptic techniques.

3.2 Preparation of equipment/instrumentation

3.2.1 On the day of test initiation, set a water bath at $36^{\circ} \pm 2^{\circ}\text{C}$.

3.2.2 On the day of test initiation, set a water bath at $56^{\circ} \pm 2^{\circ}\text{C}$.

3.3 Preparation of reagents/control procedures

3.3.1 Two days prior to test performance, seed 96-well cell culture plates with MDBK cells, in Growth Medium, at a cell count ($10^{4.7}$ to $10^{5.2}$ cells/mL) that will produce a confluent monolayer after 48 ± 8 hours of incubation at $36^{\circ} \pm 2^{\circ}\text{C}$ in a CO_2 incubator. These become the MDBK Plates. Four Test Sera may be tested per MDBK Plate.

3.3.2 On day of test initiation:

1. Working IBR Reference. Rapidly thaw a vial of IBR Reference in a $36^{\circ} \pm 2^{\circ}\text{C}$ water bath. Dilute the virus in MEM to contain 50-300 50% tissue culture infective dose (TCID_{50})/25 μL .

2. Virus Back Titration. Make 3 serial tenfold dilutions of Indicator Virus.

a. Place 900 μL of MEM into 3, 12 x 75-mm polystyrene tubes labeled 10^{-1} x 10^{-3} .

b. Transfer 100 μL of Working IBR Reference to the 10^{-1} tube; mix by vortexing. Discard pipette tip.

c. Using a new pipette tip, transfer 100 μL from the 10^{-1} tube to the 10^{-2} tube; mix by vortexing.

d. Using a new pipette tip, transfer 100 μL from the 10^{-2} tube to the 10^{-3} tube; mix by vortexing.

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

3.4 Preparation of the Test Serum, PCS, and NCS

3.4.1 On the day of test initiation, heat inactivate all Test Serum samples, PCS, and NCS in a $56^{\circ}\pm 2^{\circ}\text{C}$ water bath for 30 ± 5 minutes.

3.4.2 Prepare serial twofold dilutions of the Test Serum samples, PCS, and NCS in a 96-well cell culture plate, which becomes the Dilution Plate (**Appendix I**). A sufficient number of dilutions of the PCS should be performed to reach an endpoint for the control. Twofold dilutions are made as follows:

- 1.** Add 150 μL MEM to all wells in Rows B through D. Rows E through H may be used if additional samples are to be tested.
- 2.** Add 150 μL Test Serum samples, PCS, or NCS to Rows A and B. Mix Row B with the multichannel micropipettor (7 ± 2 fills by aspiration and expulsion of the 12-channel micropipettor).
- 3.** Using new pipette tips, transfer 150 μL from Row B to Row C. Mix Row C with the multichannel micropipettor (7 ± 2 fills).
- 4.** Repeat as in **Section 3.4.2(3)** for Row D, and discard 150 μL from all wells in Row D. Additional dilutions of Test Serum samples may be prepared if endpoint titers are desired.
- 5.** Add 150 μL of Working IBR Reference virus to all wells of the Dilution Plate; tap plates gently to mix. Incubate for 60 ± 10 minutes at $36^{\circ}\pm 2^{\circ}\text{C}$ to allow for neutralization of virus. The addition of virus results in an additional twofold dilution of Test Serum.

4. Performance of the Test

4.1 On the day of test initiation, decant Growth Medium from the MDBK Plates.

4.2 Inoculate 50 μL /well of each Virus-Serum mixture (**Section 3.4.2(5)**) into 5 wells/dilution of a MDBK Plate (**Appendix II**).

4.3 Inoculate 25 μL of each dilution of Virus Back Titration into 5 wells of a MDBK Plate.

4.4 Add 25 μL of MEM to each Virus Back Titration well

4.5 Maintain 5 or more wells on a MDBK Plate as uninoculated cell controls.

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

4.6 Incubate MDBK Plates for 60 ± 10 minutes at $36^{\circ} \pm 2^{\circ}\text{C}$ in a CO_2 incubator.

4.7 Add 200 μL /well of Maintenance Medium to all wells (do not remove Virus-Serum mix). Incubate MDBK Plate for 4 days \pm 12 hours postinoculation at $36^{\circ} \pm 2^{\circ}\text{C}$ in a CO_2 incubator.

4.8 At 4 days postinoculation, examine the wells with an inverted light microscope at 100X magnification. The CPE of IBR is visible as grape-like clusters of rounded cells in the cell monolayer where the cells have been destroyed by the virus.

Record the number of wells/dilution showing any characteristic CPE of IBR for each Test Serum and Virus Back Titration.

4.9 Calculate the titer of the Test Serum, PCS, and NCS using the Spearman-Kärber method as commonly modified.

Example:

1:2 dilution of Test Serum = 5/5 wells CPE negative
1:4 dilution of Test Serum = 5/5 wells CPE negative
1:8 dilution of Test Serum = 3/5 wells CPE negative
1:16 dilution of Test Serum = 0/5 wells CPE negative

Spearman-Kärber formula:

Test Serum titer = $(X - d/2 + [d \cdot S])$ where:

X = \log_{10} of lowest dilution (= 0.3)

d = \log_{10} of dilution factor (= 0.3)

S = sum of proportion of CPE negative

$$\frac{5}{5} + \frac{5}{5} + \frac{3}{5} + \frac{0}{5} = \frac{13}{5} = 2.6$$

$$\text{Test Serum titer} = (0.3 - 0.3/2 + [0.3 \cdot 2.6]) = 0.93$$

$$\text{antilog of } 0.93 = 8.5$$

From the example, the Test Serum has a SN titer of 1:8.5.

4.10 By the same Spearman-Kärber method, calculate the endpoint of the BVDV Back Titration. The titer is expressed as \log_{10} tissue culture infective doses 50 (TCID_{50}) per 25 μL dose.

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

Example:

10^0 dilution of the Working BVDV = 5 of 5 wells CPE Positive
 10^{-1} dilution of the Working BVDV = 5 of 5 wells CPE Positive
 10^{-2} dilution of the Working BVDV = 3 of 5 wells CPE Positive
 10^{-3} dilution of the Working BVDV = 0 of 5 wells CPE Positive

Test Serum titer = $(X - d/2 + [d \cdot S])$ where:

X = \log_{10} of lowest dilution (= 0)

d = \log_{10} of dilution factor (= 1)

S = sum of proportion of CPE positive

$$\frac{5}{5} + \frac{5}{5} + \frac{3}{5} + \frac{0}{5} = \frac{13}{5} = 2.6$$

Test Serum titer = $(0 - 1/2 + [1 \cdot 2.6]) = 2.1$

antilog of 2.1 = 125.9

Titer of the Working BVDV is 126 TCID₅₀/25 μ L dose in the test.

5. Interpretation of the Test Results

5.1 Validity requirements

5.1.1 No visible contamination or serum toxicity should be observed in more than one well/dilution of any dilution of a Test Sera or the FBS.

5.1.2 The SN titer of the PCS should vary by no more than twofold from its mean titer as established from a minimum of 10 titrations that have been previously performed.

5.1.3 The SN titer of the NCS should be < 1:2.

5.1.4 The Virus Back Titration must have between 50-300 TCID₅₀/25 μ L.

5.2 Four out of 5 postvaccinated Test Sera shall have a SN titer \geq 1:8 for a **SATISFACTORY** result as stated in 9 CFR 113.216.

5.3 Retest

5.3.1 If the initial test is valid and less than 4 out of 5 postvaccinated Test Sera have a SN titer < 1:8, the test is repeated (1st retest).

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

5.3.2 If the 2nd valid test (1st retest) confirms the initial results, the Test Serial is **UNSATISFACTORY**.

5.3.3 If the 2nd valid test (1st retest) fails to confirm the initial result, the Test Sera is tested a 3rd time (2nd retest).

1. If 4 out of 5 postvaccinated Test Sera have a SN titer $\geq 1:8$ in the 2nd and 3rd valid tests (1st and 2nd retests), the Test Serial is **SATISFACTORY**.

2. If the 3rd valid test (2nd retest) confirms the initial result, the Test Serial is **UNSATISFACTORY**.

6. Report of Test Results

Record the SN titers on the test record.

7. References

7.1 Title 9, *Code of Federal Regulations*, part 113.216, U.S. Government Printing Office, Washington, DC.

7.2 Finney, DJ. *Statistical Method in Biological Assay*. 3rd ed. Charles Griffin and Company, London, 1978.

7.3 Rose NR, H Friedman, JL Fahey, eds. *Manual of Clinical Laboratory Immunology*. Chapter 11: Neutralization Assays. ASM, Washington, DC, 1986.

8. Summary of Revisions

Version .05

- The Contact information has been updated; however, the Virology Section has elected to keep the same next review date for the document.

Version .04

- The phrase "available from the Center for Veterinary Biologics/CVB" has been removed from the document as these reagents are no longer supplied by the CVB.

UNCONTROLLED COPY

**Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)**

Version .03

- The Contact information has been updated.

Version .02

- This document was revised to clarify practices currently in use at the Center for Veterinary Biologics and to provide additional detail.
- The assay was converted from a virus plaque method utilizing Bovine Embryonic Kidney cell cultures to a microtiter cytopathic effect assay utilizing Madin Darby Kidney cell cultures.

UNCONTROLLED COPY

Supplemental Assay Method for the Titration of Bovine Rhinotracheitis Neutralizing Antibody
(Constant Virus-Varying Serum Method)

**Appendix I
Transfer Plate**

A 1:2*	TS1	TS2	TS3	TS4	TS5	TS6	TS7	TS8	TS9	TS 10	PSC	NSC
B 1:4	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
C 1:8	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
D 1:16	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
E 1:2*	TS11	TS12	TS13	TS14	TS15	TS16	TS17	TS18	TS19	TS20	↓	↓
F 1:4	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
G 1:8	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓
H 1:16	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓	↓

*Final serum dilutions

TS= Test Serum (diluted 1:2 - 1:16)

PSC= Positive control serum (final dilutions 1:2-1:16)

NCS= Negative control serum (final dilutions 1:2-1:16)

**Appendix II
Test Plate**

A 1:2	TS1	TS1	TS1	TS1	TS1	CC	CC	TS2	TS2	TS2	TS2	TS2
B 1:4												
C 1:8												
D 1:16												
E 1:2	TS3	TS3	TS3	TS3	TS3	CC	CC	TS4	TS4	TS4	TS4	TS4
F 1:4												
G 1:8												
H 1:16												

TS= Test Serum CC= Cell Control

UNCONTROLLED COPY